Related references
Note: Only part of the references are listed.Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies
Juan Carlos Polanco et al.
NATURE REVIEWS NEUROLOGY (2018)
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6
Kaichuan Zhu et al.
BIOLOGICAL PSYCHIATRY (2018)
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
Michael F. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Ulf Neumann et al.
EMBO MOLECULAR MEDICINE (2018)
Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice
Ming-Hsuan Ou-Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate
Ting Yang et al.
JOURNAL OF NEUROSCIENCE (2017)
Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage
Stephanie Villarreal et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A Peptides
Kei Sakamoto et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory
Agostino Palmeri et al.
JOURNAL OF NEUROSCIENCE (2017)
Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels
Yanjun Zhao et al.
NEURON (2017)
The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease
Zi-Xuan Wang et al.
MOLECULAR NEUROBIOLOGY (2016)
PHARMACODYNAMICS OF THE ORAL BACE INHIBITOR JNJ-54861911 IN EARLY ALZHEIMER'S DISEASE
Johannes Streffer et al.
Alzheimers & Dementia (2016)
RESULTS FROM A FIRST-IN-HUMAN STUDY WITH THE BACE INHIBITOR CNP520
Mike Ufer et al.
Alzheimers & Dementia (2016)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
Susanna Eketjall et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Jinping Wang et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Leading Alzheimer's theory survives drug failure
Alison Abbott et al.
NATURE (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Matthew E. Kennedy et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions
Severin Filser et al.
BIOLOGICAL PSYCHIATRY (2015)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609
Bruce Albala et al.
Alzheimers & Dementia (2014)
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects
Robert Vassar et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Riqiang Yan et al.
LANCET NEUROLOGY (2014)
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease
Robert Vassar
ALZHEIMERS RESEARCH & THERAPY (2014)
Brain amyloid-β oligomers in ageing and Alzheimer's disease
Sylvain E. Lesne et al.
BRAIN (2013)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Clifford R. Jack et al.
LANCET NEUROLOGY (2013)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Victor L. Villemagne et al.
LANCET NEUROLOGY (2013)
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Chia-Chan Liu et al.
NATURE REVIEWS NEUROLOGY (2013)
A tale of two drug targets: the evolutionary history of BACE1 and BACE2
Christopher Southan et al.
Frontiers in Genetics (2013)
First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing
Robert Lai et al.
Alzheimers & Dementia (2012)
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric et al.
ARCHIVES OF NEUROLOGY (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Axonal regulation of Schwann cell ensheathment and myelination
James L. Salzer
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2012)
Endogenous Amyloid-β is Necessary for Hippocampal Synaptic Plasticity and Memory
Daniela Puzzo et al.
ANNALS OF NEUROLOGY (2011)
Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass
Daria Esterhazy et al.
CELL METABOLISM (2011)
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
E. Genin et al.
MOLECULAR PSYCHIATRY (2011)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A Physiological Role for Amyloid-beta Protein: Enhancement of Learning and Memory
John E. Morley et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Decreased Clearance of CNS β-Amyloid in Alzheimer's Disease
Kwasi G. Mawuenyega et al.
SCIENCE (2010)
Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo
Ryan J. Watts et al.
Alzheimers & Dementia (2009)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Bace1 modulates myelination in the central and peripheral nervous system
Xiangyou Hu et al.
NATURE NEUROSCIENCE (2006)
Control of peripheral nerve myelination by the β-secretase BACE1
Michael Willem et al.
SCIENCE (2006)
Neuropathology of older persons without cognitive impairment from two community-based studies
D. A. Bennett et al.
NEUROLOGY (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Neurogenic effect of β-amyloid peptide in the development of neural stem cells
MA López-Toledano et al.
JOURNAL OF NEUROSCIENCE (2004)
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease
P Giannakopoulos et al.
NEUROLOGY (2003)
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
LB Yang et al.
NATURE MEDICINE (2003)
BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein
M Farzan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Expression analysis of BACE2 in brain and peripheral tissues
BD Bennett et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
